U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) (NYSE:LLY)

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 25, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application for Jardiance® (empagliflozin) based on cardiovascular risk reduction data from the landmark EMPA-REG OUTCOME® trial. Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) expect to receive a decision from the FDA within the standard review time frame.

Cardiovascular complications can have a significant impact on the health and life expectancy of people with type 2 diabetes. Approximately 50 percent of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease.

U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin) (NYSE:LLY)